Spots Global Cancer Trial Database for epcore
Every month we try and update this database with for epcore cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | NCT05578976 | Diffuse Large B... | Epcoritamab Cyclophosphamid... Rituximab Vincristine Doxorubicin Prednisone | 18 Years - 79 Years | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | NCT05201248 | B-Cell Non-Hodg... | Epcoritamab Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Lenalidomide | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | NCT05451810 | Diffuse Large B... Classic Follicu... | Epcoritamab | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | NCT05201248 | B-Cell Non-Hodg... | Epcoritamab Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Lenalidomide | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | NCT05451810 | Diffuse Large B... Classic Follicu... | Epcoritamab | 18 Years - | Genmab | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
